Group 1 - The core point of the article highlights that Hongyuan Pharmaceutical (301246.SZ) is currently experiencing a decline in stock price, closing at 14.63 yuan with a drop of 3.81%, resulting in a total market capitalization of 5.852 billion yuan [1] - The company went public on March 20, 2023, on the Shenzhen Stock Exchange's ChiNext board, issuing 47.2572 million shares at an initial price of 50.00 yuan per share [1] - On its first trading day, the stock reached a peak price of 45 yuan but has since experienced a downward trend [1] Group 2 - Hongyuan Pharmaceutical raised a total of 236.286 million yuan through its initial public offering, with a net amount of 219.58437 million yuan after deducting issuance costs, which exceeded the original plan by 154.51137 million yuan [1] - The company had initially planned to raise 65.073 million yuan for projects including a research center, multifunctional testing workshop, antiviral raw materials and intermediates project, and a high-end formulation workshop with an annual production capacity of 2.5 billion tablets [1] - The total issuance costs amounted to 16.70163 million yuan, with underwriting and sponsorship fees accounting for 13.93196 million yuan [1]
宏源药业跌3.81% 2023年上市即巅峰超募15亿